Mölnlycke Health Care AB v. Medline Industries, LP, No. 2:26-cv-13300 (C.D. Cal.), is a complaint for patent infringement filed November 13, 2026. Mölnlycke demands a jury trial under Rule 38 of the Federal Rules of Civil Procedure. The complaint describes Mölnlycke as "a leading international medical solutions company" headquartered in Gothenburg, Sweden, that manufactures and sells medical devices including wound care, single-use surgical, and pressure ulcer prevention products. It alleges, on information and belief, that Medline Industries, LP is a limited partnership formed under the laws of Illinois with a principal place of business in Northfield, Illinois. It says Medline is also in the business of selling medical products and devices, including the accused products.

The patents and the accused dressings

The complaint asserts U.S. Patent 12,251,293, titled Prophylactic Dressing, issued March 18, 2025; U.S. Patent 12,533,265, titled Medical Dressing, issued January 27, 2026; and U.S. Patent 12,636,197, titled Prophylactic Dressing, issued May 26, 2026. Mölnlycke alleges that it owns all right, title, and interest in each patent and that each patent is valid and enforceable. The accused products are described as transparent medical dressings incorporating gel pads, including at least Medline's OptiView Transparent Dressing with HydroCore Technology.

Claim 1 of the '293 patent recites a medical dressing configured to be applied on intact skin and to prevent the onset of a pressure ulcer during use. The dressing has a skin-facing surface, on its first side, adapted to detachably adhere to a dermal surface, and a gel pad arranged between a backing layer and an adhesive body contact layer that comprises a silicone based adhesive and that skin-facing surface. At least the backing layer extends beyond the periphery of the gel pad to define a border portion. A gel of the gel pad has a compressive strength of from 5 to 60 kPa at a strain of 50%, as measured according to a compression test. The gel pad, backing layer, and adhesive body contact layer are substantially transparent, which, in combination with that compressive strength, allows a caregiver to perform a blanching test through the dressing of an area covered by those layers during use.

Claim 1 of the '265 patent recites a medical dressing comprising a backing layer, a body contact layer, and a gel pad arranged between them, with the backing layer and body contact layer extending beyond a periphery of the gel pad to define a border portion around a contour of the gel pad, and with a gel of the gel pad having a compressive strength of from 1 to 30 kPa at a strain of 25% and/or from 5 to 70 kPa at a strain of 50%, as measured according to ASTM D3574-11, test C.

Claim 1 of the '197 patent recites a method of performing a blanching test that includes providing, on the skin of a subject, a medical dressing comprising a gel pad arranged between a backing layer and an adhesive body contact layer, where a gel of the gel pad has a compressive strength of from 5 to 60 kPa at a strain of 50%, as measured according to a compression test, and those layers are transparent, and performing the blanching test through the dressing of an area of the skin covered by those layers.

The three counts

Count One alleges that Medline has directly infringed and continues to directly infringe the '293 patent under 35 U.S.C. § 271(a) by making, using, offering for sale, selling, or importing the accused products, including at least Item No. MSCOV99EP (OptiView Clear Dressing, Sacrum, 9" x 9"). Citing Exhibit 4, it says those products meet each limitation of at least claims 1, 2, 6, 7, 13, 14, and 16 to 21, literally or under the doctrine of equivalents. It also alleges induced infringement of those claims under § 271(b), with knowledge or willful blindness, and alleges, on information and belief, that Medline intends to cause and has taken affirmative steps to induce infringement through advertisements, distribution channels, instructions or manuals, and technical support or services. It says Medline has had knowledge of the '293 patent since at least May 7, 2026, when Mölnlycke notified Medline of its infringement, and that Medline has continued its conduct despite that knowledge and that the conduct has been willful.

Count Two alleges direct infringement of the '265 patent under § 271(a) by making, using, offering for sale, selling, or importing the accused products, including at least Item Nos. MSCOV99EP (OptiView Sacrum), MSCOV1200BZ (OptiView Clear Dressing, Heel, 9" x 9"), MSCOVM6EP (OptiView Clear Dressing, Multisite, 6" x 6"), and MSCOV44EPZ (OptiView Clear Dressing, Bordered, 4" x 4"). Citing Exhibit 5, it says those products meet each limitation of at least claims 1 and 5, and that the OptiView Sacrum further meets at least claims 7 and 11, literally or under the doctrine of equivalents. It alleges induced infringement of claims 1 and 5 as to those products, and of claims 7 and 11 as to the OptiView Sacrum, with the same knowledge or willful blindness and, on information and belief, the same kinds of affirmative steps. It says Medline has had knowledge of the '265 patent since at least the same May 7, 2026 notice, and that Medline has continued its conduct despite that knowledge and that the conduct has been willful.

Count Three alleges that Medline has directly infringed and continues to directly infringe the '197 patent under § 271(a) by performing the patented methods, including in connection with making, using, offering for sale, selling, or importing the accused products, including at least Item No. MSCOV99EP. Citing Exhibit 6, it says Medline performs each step of claims 1 through 10, literally or under the doctrine of equivalents. It also alleges induced infringement of claims 1 through 10. It alleges, on information and belief, that Medline has had knowledge of the '197 patent since on or around May 26, 2026, when the patent issued, or at the very latest upon receipt of the complaint. It alleges that Medline has continued its conduct despite that knowledge and that the conduct has been willful.

Jurisdiction, venue, and the prayer

The complaint pleads subject matter jurisdiction under 28 U.S.C. §§ 1331 and 1338(a). It alleges personal jurisdiction because Medline has purposefully directed activities at residents of California and this district and because Mölnlycke's claims arise out of or relate to those activities. It alleges, on information and belief, that Medline markets, promotes, and sells the accused products to healthcare providers in California and this district. It alleges that Medline imports medical dressings into California and this district through the Port of Long Beach, including, on information and belief, the accused products. It also alleges that Medline offers the accused products for sale through its Medline at Home website to California residents, operates a distribution center in Rialto, California, and has announced plans to open a distribution center in Perris, California, both of which are in this district. It says venue is proper under 28 U.S.C. § 1400(b) because Medline has a regular and established place of business in the district, including at least the Rialto distribution center, and has committed acts of infringement there.

On each count, Mölnlycke seeks compensatory damages including lost profits, but in no event less than a reasonable royalty, together with interest and costs under 35 U.S.C. § 284, enhanced damages up to three times that amount, and an injunction. The prayer asks for a judgment of direct and/or induced infringement and of validity and enforceability; an injunction; an accounting and damages; a willfulness finding and enhanced damages under § 284; costs, expenses, and pre- and post-judgment interest under § 284; a finding that the case is exceptional and an award of reasonable attorneys' fees under 35 U.S.C. § 285; and such other relief as the court deems just and proper.

What to watch next

Watch for the defendant's answer, a Rule 12 motion, or a scheduling order. The case can end at any time, including by settlement or voluntary dismissal.